- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Aclarion, Inc.: Aclarion's Nociscan Solution to Play Key Role in Groundbreaking LIFEHAB Trial Evaluating the Diagnosis and Treatment of Chronic Low Back Pain | 3 | GlobeNewswire (USA) | ||
| 12.04. | Aclarion, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 28.03. | Aclarion, Inc. - 10-K, Annual Report | 2 | SEC Filings | ||
| 27.02. | Aclarion, Inc.: Aclarion Announces Closing of $3.0 Million Public Offering | 3 | GlobeNewswire (USA) | ||
| 26.02. | Aclarion stock tumbles 63% on pricing of $3M public offering | 3 | Seeking Alpha | ||
| 26.02. | Why Aclarion (ACON) Shares Are Down Over 60% Today | 2 | Benzinga.com | ||
| 26.02. | Aclarion, Inc.: Aclarion Announces Pricing of $3.0 Million Public Offering | 2 | GlobeNewswire (USA) | ||
| 26.02. | Why Is Aclarion (ACON) Stock Down 19% Today? | 3 | InvestorPlace | ||
| 21.02. | Aclarion, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 21.02. | Aclarion, Inc. - S-1/A, General form for registration of securities | 3 | SEC Filings | ||
| 05.02. | Aclarion, Inc.: Aclarion Announces Successful Financings; Plans to Launch CLARITY Trial and Provides Update on Next Steps of Alphatec Strategic Partnership | 184 | GlobeNewswire (Europe) | Company is initiating its pivotal multicenter, prospective, randomized CLARITY trial to build on clinical evidence demonstrating superior surgical outcomes when Nociscan is utilized in surgical decisioning... ► Artikel lesen | |
| 31.01. | Aclarion, Inc. - S-1/A, General form for registration of securities | 1 | SEC Filings | ||
| 29.01. | Why Is Aclarion (ACON) Stock Down 16% Today? | 1 | InvestorPlace | ||
| 26.01. | What's Going On With Healthcare Technology Penny Stock Aclarion Stock Today? | 2 | Benzinga.com | ||
| 26.01. | Why Is Aclarion (ACON) Stock Up 109% Today? | 2 | InvestorPlace | ||
| 25.01. | (ACON) - Analyzing Aclarion's Short Interest | 1 | Benzinga.com | ||
| 23.01. | Aclarion, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 22.01. | Aclarion files to sell 2.5M shares for its holder | 2 | Seeking Alpha | ||
| 22.01. | Aclarion, Inc. - S-1, General form for registration of securities | 1 | SEC Filings | ||
| 22.01. | Aclarion, Inc.: Aclarion Expands Nociscan Access Into Phoenix With Key Opinion Leader Surgeon Advisor Juan Uribe, MD | 1 | GlobeNewswire (USA) |
Seite:
1 2 Weiter >>
33 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ORPEA | 12,582 | -0,66 % | EMEIS PURSUES ITS REFOUNDATION: 2023 Consolidated Financial Results of ORPEA S.A. | Significant improvement in non-financial indicators, with major advances for employees, residents and patients
Health and safety: decline in the work-related accident frequency rate, at 24.8... ► Artikel lesen | |
| NANO-X IMAGING | 8,940 | +0,22 % | Nano-X Imaging Ltd. - 6-K, Report of foreign issuer | ||
| BUTTERFLY NETWORK | 0,780 | +10,56 % | ThinkSono Ltd: ThinkSono Releases Real-Time DVT AI Training Solution for Butterfly Network's Handheld Ultrasound Devices | LONDON, ENGLAND / ACCESSWIRE / April 23, 2024 / ThinkSono, a pioneering provider of AI-driven medical imaging solutions, is proud to announce the release of ThinkSono AI Training, a deep vein thrombosis... ► Artikel lesen | |
| GOODRX | 7,190 | +1,55 % | GoodRx Reports Fourth Quarter and Full Year 2023 Results | SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx Holdings, Inc. (Nasdaq: GDRX) ("GoodRx" or the "Company"), the leading destination for prescription savings in the U.S., has released its financial... ► Artikel lesen | |
| JOINT CORP | 12,230 | +1,24 % | The Joint Corp. Reports Fourth Quarter and Year-end 2023 Financial Results | - Grew 2023 Revenue 16%, System-wide Sales 12%, and System-wide Comp Sales 4% vs. 2022 - - Increased Clinic Count to 935 at Year-end 2023, Initiating Refranchising Program - SCOTTSDALE, Ariz., March... ► Artikel lesen | |
| CARMAT | 3,145 | -0,47 % | CARMAT Announces Its 2023 Annual Results and Provides an Update on Its Progress and Prospects for 2024 | 2023 sales of €2.8 million, i.e. 17 Aeson® implants, including 11 in the last quarter
2024 sales forecast of around €14 million
Active exploration of financing options to extend... ► Artikel lesen | |
| HYPERFINE | 0,845 | +1,68 % | Hyperfine, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results | GUILFORD, Conn., March 21, 2024 (GLOBE NEWSWIRE) -- Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable... ► Artikel lesen | |
| PROGYNY | 32,040 | -1,42 % | Progyny, Inc. Announces Details for Its First Quarter 2024 Results Report | ||
| MIMEDX | 6,265 | +0,32 % | Mimedx Group, Cyclacel Pharmaceuticals, Predictive Oncology among healthcare movers | ||
| BIOMERICA | 0,665 | -2,21 % | Biomerica, Inc.: Biomerica Reports Third Quarter 2024 Financial Results | Fiscal Discipline Leads to Improvement as Loss per Share Narrows to $0.27 from $0.40 Amidst Sales Force Expansion for the Nine Months in Fiscal 2024 InFoods IBS Positive Clinical Data to be Presented... ► Artikel lesen | |
| ATRICURE | 23,170 | +2,48 % | AtriCure upgraded at Oppenheimer on valuation | ||
| ATRION | 370,00 | -6,09 % | Dividendenbekanntmachungen (14.03.2024) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ABRDN PLC GB00BF8Q6K64 0,073 GBP 0,0853 EUR ABRDN PLC ADR US00108N1000 0,3203 USD 0,2925 EUR ACCO BRANDS CORPORATION US00081T1088 0... ► Artikel lesen | |
| OUTSET MEDICAL | 2,400 | +0,84 % | FDA labels Outset Medical recall of Tablo hemodialysis system as Class I | ||
| AMWELL | 0,529 | -2,29 % | Amwell Receives Continued Listing Standard Notice From NYSE | Boston, April 04, 2024 (GLOBE NEWSWIRE) -- Amwell® (NYSE: AMWL), a leading provider of healthcare software as a service, today announced that it received a notice on April 2, 2024 from the New York... ► Artikel lesen | |
| TALKSPACE | 3,120 | +1,30 % | Talkspace Announces Third Quarter 2023 Results | B2B payor revenue grew 132% year-over-year 3Q 2023 Operating expenses of $24.0 million, down 30% year-over-year Reduced Net Loss to $4.4 million and Adjusted EBITDA1 loss to $2.8 million, an improvement... ► Artikel lesen |
ACLARION INC gehört der Branche Gesundheitswesen an. Die relative Kursveränderung beträgt aktuell -13,50 % bei einem Aktienkurs von 0,340 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
